(Q22252861)

Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life.

21 January 2018

1 reference

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

Long-term trends in the use of complementary and alternative medical therapies in the United States

21 January 2018

1 reference

Patient perception of quality of care provided by specialists and generalists.

21 January 2018

1 reference

Double-blind Trial of Linoleic Acid in Multiple Sclerosis

21 January 2018

1 reference

7 January 2021

Why patients use alternative medicine: results of a national study

1 reference

7 January 2021

Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey

1 reference

7 January 2021

Complementary and Alternative Therapy Use in Persons with Multiple Sclerosis

1 reference

7 January 2021

Frequency of current utilisation of complementary and alternative medicine by patients with multiple sclerosis.

1 reference

7 January 2021

How frequently do patients with multiple sclerosis use complementary and alternative medicine?

1 reference

7 January 2021

The perceived benefit and satisfaction from conventional and complementary and alternative medicine (CAM) in people with multiple sclerosis

1 reference

7 January 2021

A survey of primary care physicians' perceptions of their patients' use of complementary medicine

1 reference

7 January 2021

What do people with MS want and expect from health-care services?

1 reference

7 January 2021

Why physicians need to look more closely at the use of complementary and alternative medicine by multiple sclerosis patients.

1 reference

7 January 2021

Complementary and alternative therapies for treating multiple sclerosis symptoms: a systematic review

1 reference

7 January 2021

Unconventional medicine in the United States. Prevalence, costs, and patterns of use

1 reference

7 January 2021

Double-blind study of pulsing magnetic field effects on multiple sclerosis

1 reference

7 January 2021

A controlled investigation of bodywork in multiple sclerosis.

1 reference

7 January 2021

Neural therapy in the treatment of multiple sclerosis.

1 reference

7 January 2021

A randomized pilot study of naturopathic medicine in multiple sclerosis

1 reference

7 January 2021

US military veterans' perceptions of the conventional medical care system and their use of complementary and alternative medicine

1 reference

7 January 2021

Double-blind Trial of Linoleate Supplementation of the Diet in Multiple Sclerosis

1 reference

7 January 2021

Polyunsaturated fatty acids in treatment of acute remitting multiple sclerosis

1 reference

7 January 2021

A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis

1 reference

7 January 2021

An exploratory study of the relationship between alternative therapies, functional status, and symptom severity among people with multiple sclerosis

1 reference

7 January 2021

Treatment of spasticity with repetitive magnetic stimulation; a double-blind placebo-controlled study

1 reference

7 January 2021

Use of unconventional therapies by individuals with multiple sclerosis

1 reference

7 January 2021

Reflexology treatment relieves symptoms of multiple sclerosis: a randomized controlled study

1 reference

7 January 2021

Demographic and health-related factors associated with complementary and alternative medicine (CAM) use in multiple sclerosis.

1 reference

7 January 2021

Utilization of unconventional treatments by persons with MS: is it alternative or complementary?

1 reference

7 January 2021

Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey

1 reference

7 January 2021